Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents

Frontiers in Pharmacology

Volumn 5 JUL, Issue , 2014, Pages

  Manda, Vamshi K ^a   Dale, Olivia R ^a   Awortwe, Charles ^c   Ali, Zulfiqar ^a   Khan, Ikhlas A ^a,b   Walker, Larry A ^a,b   Khan, Shabana I ^a,b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

CYP450 enzymes; Herb drug interactions; Labisia pumila; Myrsinaceae; P gp; Pxr

Indexed keywords

5 (10PENTADECENYL)RESORCINOL; ALKYLPHENOL DERIVATIVE; ARDISIMAMILLOSIDE H; BELAMCANDOL B; CYCLOSPORIN A; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEMETHYLBELAMCANDAQUINONE B; FATIMAHOL; KETOCONAZOLE; LABISIA PUMILA EXTRACT; METHANOL; MULTIDRUG RESISTANCE PROTEIN; PHENOL DERIVATIVE; PLANT EXTRACT; PREGNANE X RECEPTOR; PRIMULANIN; RIFAMPICIN; SAPONIN DERIVATIVE; TRANYLCYPROMINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; BIOCHEMICAL COMPOSITION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HERB; HERB DRUG INTERACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE ABSORPTION; LABISIA PUMILA; NONHUMAN; PLANT ROOT;

EID: 84904751635     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00178     Document Type: Article

References (33)

1. Abdul Kadir, A., Nik Hussain, N.H., Wan Bebakar, W.M., Mohd, D.M., Wan Mohammad, W.M., Hassan, Ii, Shukor, N., Kamaruddin, N.A., and Wan Mohamud, W.N. (2012). The Effect of Labisia pumila var. alata on Postmenopausal Women: A Pilot Study. Evid Based Complement Alternat Med 2012, 216525.
2. Ali, Z., and Khan, I.A. (2011). Alkyl phenols and saponins from the roots of Labisia pumila (Kacip Fatimah). Phytochemistry 72, 2075-2080. doi: 10.1016/j.phytochem.2011.06.014.
3. Alissa, E.M. (2014). Medicinal Herbs and Therapeutic Drugs Interactions. Ther Drug Monit. doi: In Press.
4. Awortwe, C., Bouic, P.J., Masimirembwa, C.M., and Rosenkranz, B. (2014). Inhibition of Major Drug Metabolizing CYPs by Common Herbal Medicines used by HIV/AIDS Patients in Africa- Implications for Herb- Drug Interactions. Drug Metab Lett 7, 83-95.
5. Chen, X.W., Serag, E.S., Sneed, K.B., Liang, J., Chew, H., Pan, S.Y., and Zhou, S.F. (2011). Clinical herbal interactions with conventional drugs: from molecules to maladies. Curr Med Chem 18, 4836-4850.
6. Chen, X.W., Sneed, K.B., Pan, S.Y., Cao, C., Kanwar, J.R., Chew, H., and Zhou, S.F. (2012). Herb-drug interactions and mechanistic and clinical considerations. Curr Drug Metab 13, 640-651.
7. Choi, C.H., Kang, G., and Min, Y.D. (2003). Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng. Planta Med 69, 235-240.
8. Colalto, C. (2010). Herbal interactions on absorption of drugs: Mechanisms of action and clinical risk assessment. Pharmacol Res 62, 207-227.
9. Crespi, C.L., Miller, V.P., and Penman, B.W. (1997). Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal Biochem 248, 188-190.
10. Doligalska, M., Jozwicka, K., Kiersnowska, M., Mroczek, A., Paczkowski, C., and Janiszowska, W. (2011). Triterpenoid saponins affect the function of P-glycoprotein and reduce the survival of the free-living stages of Heligmosomoides bakeri. Vet Parasitol 179, 144-151.
11. Fathilah, S.N., Mohamed, N., Muhammad, N., Mohamed, I.N., Soelaiman, I.N., and Shuid, A.N. (2013). Labisia pumila regulates bone-related genes expressions in postmenopausal osteoporosis model. BMC Complement Altern Med 13, 217.
12. Giacomini, K.M., Huang, S.M., Tweedie, D.J., Benet, L.Z., Brouwer, K.L., Chu, X., Dahlin, A., Evers, R., Fischer, V., Hillgren, K.M., Hoffmaster, K.A., Ishikawa, T., Keppler, D., Kim, R.B., Lee, C.A., Niemi, M., Polli, J.W., Sugiyama, Y., Swaan, P.W., Ware, J.A., Wright, S.H., Yee, S.W., Zamek-Gliszczynski, M.J., and Zhang, L. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9, 215-236.
13. Goodwin, B., Hodgson, E., and Liddle, C. (1999). The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56, 1329-1339.
14. Ho, P.C., Saville, D.J., and Wanwimolruk, S. (2001). Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci 4, 217-227.
15. Huang, S.M., Strong, J.M., Zhang, L., Reynolds, K.S., Nallani, S., Temple, R., Abraham, S., Habet, S.A., Baweja, R.K., Burckart, G.J., Chung, S., Colangelo, P., Frucht, D., Green, M.D., Hepp, P., Karnaukhova, E., Ko, H.S., Lee, J.I., Marroum, P.J., Norden, J.M., Qiu, W., Rahman, A., Sobel, S., Stifano, T., Thummel, K., Wei, X.X., Yasuda, S., Zheng, J.H., Zhao, H., and Lesko, L.J. (2008). New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 48, 662-670.
16. Karimi, E., Jaafar, H.Z., and Ahmad, S. (2013). Antifungal, anti-inflammatory and cytotoxicity activities of three varieties of labisia pumila benth: from microwave obtained extracts. BMC Complement Altern Med 13, 20.
17. Lehmann, J.M., Mckee, D.D., Watson, M.A., Willson, T.M., Moore, J.T., and Kliewer, S.A. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102, 1016-1023. doi: 10.1172/jci3703.
18. Li, T., and Chiang, J.Y. (2006). Rifampicin induction of CYP3A4 requires pregnane X receptor cross talk with hepatocyte nuclear factor 4alpha and coactivators, and suppression of small heterodimer partner gene expression. Drug Metab Dispos 34, 756-764.
19. Liu, R., Qin, M., Hang, P., Liu, Y., Zhang, Z., and Liu, G. (2012). Effects of Panax notoginseng saponins on the activities of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 in rats in vivo. Phytother Res 26, 1113-1118.
20. Liu, X.L., Tee, H.W., and Go, M.L. (2008). Functionalized chalcones as selective inhibitors of Pglycoprotein and breast cancer resistance protein. Bioorg Med Chem 16, 171-180.
21. Manda, V.K., Avula, B., Ali, Z., Khan, I.A., Walker, L.A., and Khan, S.I. (2014). Evaluation of in vitro ADME properties of mitragynine, 7-hydroxymitragynine, and mitraphylline Planta Med (Accepted).
22. Manda, V.K., Avula, B., Ali, Z., Wong, Y.H., Smillie, T.J., Khan, I.A., and Khan, S.I. (2013). Characterization of in vitro ADME properties of diosgenin and dioscin from Dioscorea villosa. Planta Med 79, 1421-1428.
23. Martin, C., Berridge, G., Higgins, C.F., Mistry, P., Charlton, P., and Callaghan, R. (2000). Communication between multiple drug binding sites on P-glycoprotein. Mol Pharmacol 58, 624-632.
24. Nadia, M.E., Nazrun, A.S., Norazlina, M., Isa, N.M., Norliza, M., and Ima Nirwana, S. (2012). The Anti-Inflammatory, Phytoestrogenic, and Antioxidative Role of Labisia pumila in Prevention of Postmenopausal Osteoporosis. Adv Pharmacol Sci 2012, 706905.
25. Naritomi, Y., Teramura, Y., Terashita, S., and Kagayama, A. (2004). Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab Pharmacokinet 19, 55-61.
26. Pan, Y., Tiong, K.H., Abd-Rashid, B.A., Ismail, Z., Ismail, R., Mak, J.W., and Ong, C.E. (2012). Inhibitory effects of cytochrome P450 enzymes CYP2C8, CYP2C9, CYP2C19 and CYP3A4 by Labisia pumila extracts. J Ethnopharmacol 143, 586-591.
27. Rautio, J., Humphreys, J.E., Webster, L.O., Balakrishnan, A., Keogh, J.P., Kunta, J.R., Serabjit-Singh, C.J., and Polli, J.W. (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34, 786-792.
28. Riley, R.J., Grime, K., and Weaver, R. (2007). Time-dependent CYP inhibition. Expert Opin Drug Metab Toxicol 3, 51-66.
29. Sekiguchi, N., Higashida, A., Kato, M., Nabuchi, Y., Mitsui, T., Takanashi, K., Aso, Y., and Ishigai, M. (2009). Prediction of drug-drug interactions based on time-dependent inhibition from high throughput screening of cytochrome P450 3A4 inhibition. Drug Metab Pharmacokinet 24, 500-510.
30. Singh, G.D., Ganjoo, M., Youssouf, M.S., Koul, A., Sharma, R., Singh, S., Sangwan, P.L., Koul, S., Ahamad, D.B., and Johri, R.K. (2009). Sub-acute toxicity evaluation of an aqueous extract of Labisia pumila, a Malaysian herb. Food Chem Toxicol 47, 2661-2665.
31. Stresser, D.M., and Kupfer, D. (1997). Catalytic characteristics of CYP3A4: requirement for a phenolic function in ortho hydroxylation of estradiol and mono-O-demethylated methoxychlor. Biochemistry 36, 2203-2210.
32. Venkatakrishnan, K., Obach, R.S., and Rostami-Hodjegan, A. (2007). Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica 37, 1225-1256.
33. Zhang, L., Zhang, Y.D., Zhao, P., and Huang, S.M. (2009). Predicting drug-drug interactions: an FDA perspective. AAPS J 11, 300-306. doi: 10.1208/s12248-009-9106-3.